Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 5/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | PDE5A | O76074 | 1/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL996565 | 0.91 | ALDH1A1 (0.49) | ESR1GRM2OPRK1ALDH1A1KDM4E | |
| SCHEMBL998539 | 0.87 | ALDH1A1 (0.47) | ESR1OPRK1ALDH1A1BRD4PDE3B | |
| SCHEMBL23531481 | 0.82 | OPRK1 (0.41) | ESR1GRM2OPRK1ALDH1A1BRD4 | |
| SCHEMBL998566 | 0.80 | OPRK1 (0.48) | ESR1GRM2OPRK1ALDH1A1BRD4 | |
| SCHEMBL15135178 | 0.79 | OPRK1 (0.39) | ESR1GRM2OPRK1ALDH1A1BRD4 | |
| SCHEMBL4594720 | 0.78 | BRD4 (0.45) | OPRK1ALDH1A1BRD4PDE3BPDE3A | |
| SCHEMBL9444420 | 0.77 | ESR1 (0.64) | ESR1ALDH1A1BRD4ADORA2AADORA2B | |
| SCHEMBL996418 | 0.76 | GRM2 (0.48) | GRM2OPRK1BRD4 | |
| SCHEMBL23531424 | 0.76 | MAOB (0.51) | — | |
| SCHEMBL23531473 | 0.74 | HSD17B10 (0.47) | OPRK1ALDH1A1GAAKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9233937-B2 | Method of stimulating insulin secretion and/or modulating INS-1 kinase with substituted pyrazinones and/or substituted tetrahydroquinoxalinones | MERCK PATENT GMBH (FR) | 2016-01-12 | — | — | US | claimed |
| US-20140329837-A1 | ARYLPYRAZINONES SUCH AS BUT NOT LIMITED TO 3-(4-CHLOROPHENYL-1-ETHYLPYRAZIN-2-(1H0)-ONE | MERCK PATENT GMBH (FR) | 2014-11-06 | — | — | US | claimed |
| US-8815859-B2 | Substituted pyrazin-2-ones and substituted 5,6,7,8-tetrahydroquinoxalin-2-ones and methods of use thereof | MERCK PATENT GMBH (DE) | 2014-08-26 | — | — | US | claimed |
| EP-2268624-B1 | ARYLPYRAZINONE DERIVATIVES INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2013-07-31 | — | — | EP | claimed |
| US-20110046159-A1 | Arylpyrazinone derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK PATENT GESELLSCHAFT (DE) | 2011-02-24 | — | — | US | claimed |
| US-9233937-B2 | Method of stimulating insulin secretion and/or modulating INS-1 kinase with substituted pyrazinones and/or substituted tetrahydroquinoxalinones | MERCK PATENT GMBH (FR) | 2016-01-12 | — | — | US | disclosed |
| US-9233937-B2 | Method of stimulating insulin secretion and/or modulating INS-1 kinase with substituted pyrazinones and/or substituted tetrahydroquinoxalinones | MERCK PATENT GMBH (FR) | 2016-01-12 | — | — | US | disclosed |
| US-9233937-B2 | Method of stimulating insulin secretion and/or modulating INS-1 kinase with substituted pyrazinones and/or substituted tetrahydroquinoxalinones | MERCK PATENT GMBH (FR) | 2016-01-12 | — | — | US | disclosed |
| US-20140329837-A1 | ARYLPYRAZINONES SUCH AS BUT NOT LIMITED TO 3-(4-CHLOROPHENYL-1-ETHYLPYRAZIN-2-(1H0)-ONE | MERCK PATENT GMBH (FR) | 2014-11-06 | — | — | US | disclosed |
| US-20140329837-A1 | ARYLPYRAZINONES SUCH AS BUT NOT LIMITED TO 3-(4-CHLOROPHENYL-1-ETHYLPYRAZIN-2-(1H0)-ONE | MERCK PATENT GMBH (FR) | 2014-11-06 | — | — | US | disclosed |
| US-20140329837-A1 | ARYLPYRAZINONES SUCH AS BUT NOT LIMITED TO 3-(4-CHLOROPHENYL-1-ETHYLPYRAZIN-2-(1H0)-ONE | MERCK PATENT GMBH (FR) | 2014-11-06 | — | — | US | disclosed |
| US-8815859-B2 | Substituted pyrazin-2-ones and substituted 5,6,7,8-tetrahydroquinoxalin-2-ones and methods of use thereof | MERCK PATENT GMBH (DE) | 2014-08-26 | — | — | US | disclosed |
| EP-2268624-B1 | ARYLPYRAZINONE DERIVATIVES INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2013-07-31 | — | — | EP | disclosed |
| EP-2268624-B1 | ARYLPYRAZINONE DERIVATIVES INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2013-07-31 | — | — | EP | disclosed |
| US-20110046159-A1 | Arylpyrazinone derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK PATENT GESELLSCHAFT (DE) | 2011-02-24 | — | — | US | disclosed |
| US-20110046159-A1 | Arylpyrazinone derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK PATENT GESELLSCHAFT (DE) | 2011-02-24 | — | — | US | disclosed |
| US-20110046159-A1 | Arylpyrazinone derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK PATENT GESELLSCHAFT (DE) | 2011-02-24 | — | — | US | disclosed |
| EP-2268624-A1 | ARYLPYRAZINONE DERIVATIVES INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES | Merck Patent GmbH (DE) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009132739-A1 | ARYLPYRAZINONE DERIVATIVES INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2009-11-05 | — | — | WO | disclosed |
| WO-2009132739-A1 | ARYLPYRAZINONE DERIVATIVES INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329837-A1 | ARYLPYRAZINONES SUCH AS BUT NOT LIMITED TO 3-(4-CHLOROPHENYL-1-ETHYLPYRAZIN-2-(1H0)-ONE | IAPP, GPR119, GLP1R | ESR1 2115/4885GRM2 3858/4885OPRK1 3248/4885 |
| US-20110046159-A1 | Arylpyrazinone derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | GLP1R, GPR119, IAPP | ESR1 956/4885GRM2 3626/4885OPRK1 3230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.